



(11) **EP 1 154 020 A2**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:
14.11.2001 Bulletin 2001/46

(51) Int Cl.7: **C12N 15/31, C12N 1/21,**
C07K 14/34

(21) Application number: 01109457.0

(22) Date of filing: 24.04.2001

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 28.04.2000 JP 2000129167

(71) Applicant: Ajinomoto Co., Ltd.
Tokyo (JP)

(72) Inventors:
• Suga, Mikiko, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)

- Asakura, Yoko, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)
- Mori, Yukiko, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)
- Ito, Hisao, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)
- Kurahashi, Osamu, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)

(74) Representative: **HOFFMANN - EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine**

(57) L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a

gene coding for the repressor, and which has L-arginine producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

EP 1 154 020 A2

DescriptionField of the Invention

5 [0001] The present invention relates to a coryneform bacterium having an ability to produce L-arginine and a method for producing L-arginine using the bacterium. L-arginine is an industrially useful amino acid as an ingredient of liver function promoting agents, amino acid infusions, comprehensive amino acid pharmaceuticals and so forth.

Description of the Related Art

10 [0002] Conventional L-arginine production by fermentation has been performed by utilizing wild-type strains of coryneform bacteria; coryneform bacteria resistant to certain agents including sulfa drugs, 2-thiazolealanine, α -amino- β -hydroxyvaleric acid and the like; coryneform bacteria exhibiting auxotrophy for L-histidine, L-proline, L-threonine, L-isoleucine, L-methionine, or L-tryptophan in addition to the resistance to 2-thiazolealanine (Japanese Patent Laid-open No. 54-44096); coryneform bacteria resistant to ketomalonic acid, fluoromalonic acid, or monofluoroacetic acid (Japanese Patent Laid-open No. 57-18989); coryneform bacteria resistant to argininol (Japanese Patent Laid-open No. 62-24075); coryneform bacteria resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open No. 2-186995) or the like.

20 [0003] On the other hand, there have also been disclosed methods for producing L-arginine utilizing recombinant DNA techniques. That is, there has been disclosed a method for producing L-arginine by utilizing a microorganism belonging to the genus *Corynebacterium* or *Brevibacterium* which is made to harbor a recombinant DNA comprising a vector DNA and a DNA fragment containing genes for acetylornithine deacetylase, N-acetylglutamic acid- α -semialdehyde dehydrogenase, N-acetyl glutamokinase, and argininosuccinase derived from a microorganism belonging to the genus *Escherichia* (Japanese Patent Publication No. 5-23750).

25 [0004] Further, as for coryneform bacteria, it has been elucidated that synthesis of some enzymes of the L-arginine biosynthetic system is repressed by L-arginine. Furthermore, it was reported that, while some of enzymes of L-arginine biosynthetic system were repressed by L-arginine, the repression of these enzymes by L-arginine was canceled in mutant strains of coryneform bacteria showing improved L-arginine accumulation amounts (*Agric. Biol. Chem.*, 43(1), 105, 1979).

30 [0005] Meanwhile, as for *Escherichia coli*, a repressor of L-arginine biosynthetic system and a gene coding for the repressor were identified (*Proc. Natl. Acad. Sci. U.S.A.* (1987), 84(19), 6697-701), and binding interactions of the repressor protein and various genes of L-arginine biosynthetic system were also investigated (*Proc. Natl. Acad. Sci. U.S.A.* (1987), 84(19), 6697-701, *J. Mol. Biol.* (1992), 226, 367-386).

35 [0006] However, any repressor proteins of the L-arginine biosynthetic system have not been identified in coryneform bacteria. While a nucleotide sequence of the repressor protein gene (*argR*) and an amino acid sequence assumed to be encoded thereby are registered in a gene database, GenBank (AF049897), the gene is considered to be designated *argR* because of the homology between the aforementioned amino acid sequence and known arginine repressors.

Summary of the Invention

40 [0007] As described above, although a repressor protein of the L-arginine biosynthetic system of coryneform bacteria and a gene thereof are expected, the repressor protein itself has not been identified and its functions and so forth are not elucidated at all. Therefore, an object of the present invention is to identify the repressor of the L-arginine biosynthesis in coryneform bacteria, and improve L-arginine productivity of coryneform bacteria.

45 [0008] The inventors of the present invention isolated a homologue of the gene registered as *argR* in the gene database (GenBank accession AF049897) from a coryneform bacterium, and found that, if this gene was amplified in coryneform bacteria, L-arginine producing ability was decreased, and on the other hand, if the gene was disrupted, the L-arginine producing ability was improved, to confirm that the L-arginine biosynthesis is repressed by a repressor in coryneform bacteria like *Escherichia coli* and the aforementioned gene registered as *argR* codes for the repressor. Thus, the present invention was accomplished.

50 [0009] That is, the present invention provides the followings.

- (1) A coryneform bacterium in which an arginine repressor does not function in a normal manner, and which has L-arginine producing ability.
- 55 (2) The coryneform bacterium according to (1), wherein the arginine repressor does not function in a normal manner due to disruption of a gene coding for the arginine repressor on a chromosome of the bacterium.
- (3) The coryneform bacterium according to (2), wherein the arginine repressor has the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence showing homology to the amino acid sequence.

(4) A method for producing L-arginine, which comprises culturing a coryneform bacterium according to any one of (1) to (3) in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

[0010] In the present invention, the "arginine repressor" refers to a protein that has an effect of repressing the L-arginine biosynthesis, and if expression amount of the gene that codes for the protein increases in coryneform bacteria, L-arginine producing ability will be reduced, and if the expression amount decreases or the protein disappears, the L-arginine producing ability will be improved. Hereafter, the gene coding for the arginine repressor is also called *argR* gene. Further, the "L-arginine producing ability" used in the present invention refers to an ability of the microorganism of the present invention to accumulate L-arginine in a medium, when it is cultured in the medium.

[0011] According to the present invention, L-arginine producing ability of coryneform bacteria having the L-arginine producing ability can be improved.

Brief Explanation of the Drawings

[0012] Fig. 1 shows the construction process of plasmid pK1.

[0013] Fig. 2 shows the construction process of plasmid pSFK6.

[0014] Fig. 3 shows the construction process of plasmid pSFKT2.

[0015] Hereafter, the present invention will be explained in detail.

[0016] The microorganism of the present invention is a coryneform bacterium having L-arginine producing ability, in which arginine repressor does not function in a normal manner. The coryneform bacterium of the present invention may be a microorganism having the L-arginine producing ability because an arginine repressor does not function in a normal manner in it, or a microorganism bred so that the arginine repressor should not function in a normal manner in it. Alternatively, it may be a microorganism that is bred so that the arginine repressor should not function in a normal manner in it and then imparted with the L-arginine producing ability.

[0017] The coryneform bacteria include bacteria having been hitherto classified into the genus *Brevibacterium* but united into the genus *Corynebacterium* at present (*Int. J. Syst. Bacteriol.*, 41, 255 (1981)), and include bacteria belonging to the genus *Brevibacterium* closely relative to the genus *Corynebacterium*. Examples of such coryneform bacteria include the followings.

Corynebacterium acetoacidophilum
Corynebacterium acetoglutamicum
Corynebacterium alkanolyticum
Corynebacterium callunae
Corynebacterium glutamicum
Corynebacterium lilium (*Corynebacterium glutamicum*)
Corynebacterium melassecola
Corynebacterium thermoaminogenes
Corynebacterium herculis
Brevibacterium divaricatum (*Corynebacterium glutamicum*)
Brevibacterium flavum (*Corynebacterium glutamicum*)
Brevibacterium immariophilum
Brevibacterium lactofermentum (*Corynebacterium glutamicum*)
Brevibacterium roseum
Brevibacterium saccharolyticum
Brevibacterium thiogenitalis
Brevibacterium album
Brevibacterium cerinum
Microbacterium ammoniaphilum

[0018] While the coryneform bacteria that have the L-arginine-producing ability are not particularly limited so long as they have the L-arginine-producing ability, they include, for example, wild-type strains of coryneform bacteria; coryneform bacteria resistant to certain agents including sulfa drugs, 2-thiazolealanine, α -amino- β -hydroxyvaleric acid and the like; coryneform bacteria exhibiting auxotrophy for L-histidine, L-proline, L-threonine, L-isoleucine, L-methionine, or L-tryptophan in addition to the resistance to 2-thiazolealanine (Japanese Patent Laid-open No. 54-44096); coryneform bacteria resistant to ketomalonic acid, fluoromalonic acid, or monofluoroacetic acid (Japanese Patent Laid-open No. 57-18989); coryneform bacteria resistant to argininol (Japanese Patent Laid-open No. 62-24075); coryneform bacteria resistant to X-guanidine (X represents a derivative of fatty acid or aliphatic chain, Japanese Patent Laid-open

No. 2-186995) and the like.

[0019] Specifically, the following strains can be exemplified.

- Brevibacterium flavum* AJ11169 (BP-6892)
- 5 *Corynebacterium glutamicum* AJ12092 (FERM BP-6906)
- Brevibacterium flavum* AJ11336 (FERM BP-6893)
- Brevibacterium flavum* AJ11345 (FERM BP-6894)
- Corynebacterium glutamicum* AJ12430 (FERM BP-2228)

10 [0020] The AJ11169 strain and the AJ12092 strain are the 2-thiazolealanine resistant strains mentioned in Japanese Patent Laid-open No. 54-44096, the AJ11336 strain is the strain having argininosuccinate resistance and sulfadiazine resistance mentioned in Japanese Patent Publication No. 62-24075, the AJ11345 strain is the strain having argininosuccinate resistance, 2-thiazolealanine resistance, sulfaguanidine resistance, and exhibiting histidine auxotrophy mentioned in Japanese Patent Publication No. 62-24075, and the AJ12430 strain is the strain having octylguanidine resistance and 2-thiazolealanine resistance mentioned in Japanese Patent Laid-open No. 2-186995.

15 [0021] AJ11169 was deposited on August 3, 1977 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry (currently National Institute of Bioscience and Human Technology, National Institute of Advanced Industrial Science and Technology, Ministry of Economy, Trade and Industry)(zip code: 305-8566, 1-3 Higashi 1-Chome, Tsukuba-shi, Ibaraki-ken, Japan), as deposition number of FERM P-4161, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6892.

20 [0022] AJ12092 was deposited on September 29, 1983 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-7273, and transferred from the original deposit to international deposit based on Budapest Treaty on October 1, 1999, and has been deposited as deposition number of FERM BP-6906.

25 [0023] AJ11336 was deposited on April 25, 1979 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-4939, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6893.

30 [0024] AJ11345 was deposited on April 25, 1979 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology, Ministry of International Trade and Industry, as deposition number of FERM P-4948, and transferred from the original deposit to international deposit based on Budapest Treaty on September 27, 1999, and has been deposited as deposition number of FERM BP-6894.

35 [0025] AJ12430 was deposited on December 26, 1988 in National Institute of Bioscience and Human Technology, Agency of Industrial Science and Technology of Ministry, International Trade and Industry based on Budapest Treaty, as deposition number of FERM BP-2228.

[0026] The coryneform bacterium whose arginine repressor does not function in a normal manner can be obtained by modifying its *argR* gene so that the activity of the arginine repressor should be reduced or eliminated, or the transcription of the *argR* gene should be reduced or eliminated. Such a coryneform bacterium can be obtained by, for example, replacing the chromosomal *argR* gene with an *argR* gene that does not function in a normal manner (occasionally referred to as "disrupted *argR* gene" hereinafter) through, for example, homologous recombination based on genetic recombination techniques (Experiments in Molecular Genetics, Cold Spring Harbor Laboratory Press (1972); Matsuyama, S. and Mizushima, S., *J. Bacteriol.*, 162, 1196 (1985)).

40 [0027] In the homologous recombination, when a plasmid carrying a sequence exhibiting homology with a chromosomal sequence or the like is introduced into a corresponding bacterial cell, recombination occurs at a site of the homologous sequence at a certain frequency, and thus the introduced plasmid as a whole is integrated into the chromosome. Then, by causing recombination again at the site of the homologous sequence in the chromosome, the plasmid may be removed from the chromosome. However, depending on the position at which the recombination is caused, the disrupted gene may remain on the chromosome, while the original normal gene may be removed from the chromosome together with the plasmid. By selecting such a bacterial strain, a bacterial strain in which the normal *argR* gene is replaced with a disrupted *argR* gene can be obtained.

45 [0028] Such a gene disruption technique based on the homologous recombination has already been established, and a method utilizing a linear DNA, method utilizing temperature sensitive plasmid or the like can be used therefor. The *argR* gene can also be disrupted by using a plasmid that contains the *argR* gene inserted with a marker gene such as drug resistance gene, and cannot replicate in a target cell of the coryneform bacterium. That is, in a transformant that has been transformed with such a plasmid and hence acquired drug resistance, the marker gene is integrated in a chromosome DNA. It is likely that this marker gene has been integrated by homologous recombination of the *argR* gene present at the both sides of the marker with the *argR* on the chromosome, and therefore a gene-disrupted strain

can efficiently be selected.

[0029] Specifically, a disrupted *argR* gene used for the gene disruption can be obtained by deletion of a certain region of *argR* gene by means of digestion with restriction enzyme(s) and religation; by insertion of another DNA fragment (marker gene etc.) into the *argR* gene, by introducing substitution, deletion, insertion, addition or inversion of one or more nucleotides in a nucleotide sequence of coding region of *argR* gene, its promoter region or the like by means of site-specific mutagenesis (Kramer, W. and Frits, H. J., *Methods in Enzymology*, 154, 350 (1987)) or treatment with a chemical reagent such as sodium hyposulfite and hydroxylamine (Shortle, D. and Nathans, D., *Proc. Natl. Acad. Sci. U.S.A.*, 75, 270(1978)) or the like, so that the activity of the encoded repressor should be reduced or eliminated, or transcription of the *argR* gene should be reduced or eliminated. Among these embodiments, a method utilizing deletion of a certain region of the *argR* gene by digestion with a restriction enzyme and religation, or insertion of another DNA fragment into the *argR* gene is preferred in view of reliability and stability.

[0030] A plasmid for the *argR* gene disruption can be produced by performing PCR (polymerase chain reaction) using a plasmid containing the *argR* gene and its flanking regions as a template and primers corresponding the terminal portions or flanking regions of the *argR* gene to amplify a portion except for an internal portion or the whole portion of the *argR* gene, and cyclizing the obtained amplified product. In the examples mentioned hereinafter, the *argR* gene was disrupted by this method.

[0031] The *argR* gene can be obtained from a chromosomal DNA of a coryneform bacterium by PCR using oligonucleotides prepared based on known nucleotide sequences of the *argR* gene as primers. The *argR* gene can also be obtained from a chromosome DNA library of a microorganism which has a purine operon by a hybridization technique using an oligonucleotide prepared based on a known nucleotide sequence of the *argR* gene as a probe. For the purpose of the present invention, because the *argR* gene is used for preparing a disrupted *argR* gene, it is not necessarily required to contain the full length, and it may contain a length required to cause gene disruption.

[0032] The origin of the *argR* gene is not particularly limited, so long as it has such a degree of homology that it should cause homologous recombination with the *argR* gene of coryneform bacteria. Specifically, the *argR* gene of the *Brevibacterium flavum*, which has the nucleotide sequence shown in SEQ ID NO: 17, and the *argR* gene of *Corynebacterium glutamicum* (GenBank accession AF049897) can be mentioned as the *argR* genes of coryneform bacteria. These *argR* genes are highly homologous, and it is considered that even an *argR* gene of coryneform bacterium of a genus or species different from that of a coryneform bacterium of which *argR* gene is to be disrupted may also be used for the gene disruption.

[0033] In the present invention, the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence exhibiting homology to the amino acid sequence means an amino acid sequence that is encoded by an *argR* gene having such a degree of homology that it should cause homologous recombination with the *argR* gene coding to the amino acid sequence shown in SEQ ID NO: 18 (for example, an *argR* gene having the nucleotide sequence shown in SEQ ID NO: 17).

[0034] As the primers used for PCR, any primers that allow amplification of the *argR* gene can be used. Specific examples thereof include the oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 19 and 20.

[0035] Further, examples of marker gene include drug resistance genes such as a kanamycin resistance gene. A kanamycin resistance gene can be obtained by PCR amplification from a known plasmid containing a kanamycin resistance gene of *Streptococcus faecalis*, for example, pDG783 (Anne-Marie Guerout-Fleury *et al.*, *Gene*, 167, 335-337 (1995)).

[0036] When a drug resistance gene is used as the marker gene, an *argR* gene-disrupted strain can be obtained by inserting the drug resistance gene into a suitable site of the *argR* gene carried by a plasmid, transforming a microorganism with the plasmid, and selecting a drug resistant transformant. Disruption of *argR* gene on a chromosome can be confirmed by analyzing the *argR* gene or the marker gene on the chromosome by Southern blotting, PCR, or the like. Integration of the kanamycin resistance gene into a chromosomal DNA can be confirmed by PCR using primers that allow amplification of the kanamycin resistance gene (e.g., oligonucleotides having nucleotide sequences shown in SEQ ID NOS: 1 and 2).

[0037] L-arginine can be efficiently produced by culturing a coryneform bacterium having L-arginine producing ability obtained as described above, in which an arginine repressor does not function in a normal manner, in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

[0038] The medium to be used may be selected from well-known media conventionally used for fermentative production of amino acids utilizing microorganisms. That is, it may be a usual medium that contains a carbon source, nitrogen source, inorganic ions, and other organic ingredients as required.

[0039] As the carbon source, there can be used saccharides such as glucose, sucrose, lactose, galactose, fructose or starch hydrolysate, alcohols such as glycerol or sorbitol, or organic acids such as fumaric acid, citric acid or succinic acid.

[0040] As the nitrogen source, there can be used inorganic ammonium salts such as ammonium sulfate, ammonium chloride or ammonium phosphate, organic nitrogen such as soybean protein hydrolysate, ammonia gas, aqueous

ammonia and so forth.

[0041] It is desirable to add required substances such as vitamin B₁ and L-homoserine, yeast extract and so forth to the medium in appropriate amounts as organic trace nutrients. Other than the above, potassium phosphate, magnesium sulfate, iron ion, manganese ion and so forth are added in small amounts as required.

[0042] The culture is preferably carried out under an aerobic condition for 1-7 days. The culture temperature is preferably controlled to be 24°C to 37°C, and pH is preferably controlled to be 5-9 during the culture. Inorganic or organic, acidic, alkaline substances, or ammonia gas and so forth can be used for pH adjustment. L-arginine can be collected from the fermentation broth usually by a combination of well-known techniques such as ion exchange resin techniques and other techniques.

Best Mode for Carrying out the Invention

[0043] Hereafter, the present invention will be explained more specifically with reference to the following examples.

Example 1: Constructions of shuttle vector for *Escherichia coli* and coryneform bacteria and temperature sensitive vector

[0044] First, a vector for introducing an *argR* gene into coryneform bacteria and a temperature sensitive vector for producing an *argR* deficient strain of coryneform bacterium were constructed.

<1> Construction of vector having drug resistance gene of *Streptococcus faecalis*

[0045] The kanamycin resistance gene of *Streptococcus faecalis* was amplified by PCR from a known plasmid containing the gene. The nucleotide sequence of the kanamycin resistance gene of *Streptococcus faecalis* has already been elucidated (Trieu-Cuot, P. and Courvalin, P.: *Gene*, 23 (3), 331-341 (1983)). Based on this sequence, the primers shown in SEQ ID NOS: 1 and 2 were synthesized, and PCR was performed by using pDG783 (Anne-Marie Guerout-Fleury, *et al.*, *Gene*, 167, 335-337 (1995)) as a template to amplify a DNA fragment containing the kanamycin resistance gene and its promoter.

[0046] The aforementioned DNA fragment was purified by using SUPREC02 produced by Takara Shuzo Co., Ltd., and then completely digested with restriction enzymes *Hind*III and *Hind*I to be blunt-ended. The blunt-ending was performed by using Blunting Kit produced by Takara Shuzo Co., Ltd. This DNA fragment was mixed with a DNA fragment obtained by purification and blunt-ending of an amplification product of PCR performed by using the primers shown in SEQ ID NOS: 3 and 4 and pHSG399 (see S. Takeshita, *et al.*: *Gene*, 61, 63-74 (1987)) as a template, and ligated both fragments. The ligation was performed by using DNA Ligation Kit Ver. 2 produced by Takara Shuzo Co., Ltd. Competent cells of *Escherichia coli* JM109 (produced by Takara Shuzo Co., Ltd.) were transformed with the ligated DNA, plated on L medium (10 g/L of Bacto trypton, 5 g/L of Bacto yeast extract, 5 g/L of NaCl, 15 g/L of agar, pH 7.2) containing 10 µg/ml of IPTG (isopropyl-β-D-thiogalactopyranoside), 40 µg/ml of X-Gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside) and 25 µg/ml of kanamycin, and cultured overnight. The emerged blue colonies were picked up, and separated into single colonies to obtain transformant strains.

[0047] Plasmids were prepared from the transformant strains by the alkali method (Seibutsu Kogaku Jikkensyo (Text for Bioengineering Experiments), Edited by the Society for Bioscience and Bioengineering, Japan, p.105, Baifukan, 1992), and restriction maps were prepared. One having a restriction map equivalent to that of Fig. 1 was designated as pK1. This plasmid is stably harbored in *Escherichia coli*, and imparts kanamycin resistance to a host. Moreover, since it contains the *lacZ'* gene, it is suitably used as a cloning vector.

<2> Construction of shuttle vector pSFK6

[0048] As a material for obtaining a temperature sensitive replication control region, a plasmid vector autonomously replicable in both of *Escherichia coli* cells and coryneform bacteria cells was prepared. The plasmid pAM330 extracted from *Brevibacterium lactofermentum* ATCC13869 [see Japanese Patent Publication Laid-open (Kokai) No. 58-67699] was completely digested with a restriction enzyme *Hind*III, and blunt-ended. This fragment was ligated to a fragment obtained by completely digesting the aforementioned pK1 with a restriction enzyme *Bsa*AI. *Brevibacterium lactofermentum* ATCC13869 was transformed with the ligated DNA. The transformation was performed by the electric pulse method [see Japanese Patent Publication Laid-open (Kokai) No. 2-207791]. Transformants were selected on an M-CM2B plate (10 g/L of polypeptone, 10 g/L of yeast extract, 5 g/L of NaCl, 10 µg/L of biotin, 15 g/L of agar, pH 7.2) containing 25 µg/ml of kanamycin. After cultivation for 2 days, colonies were picked up, and separated into single colonies to obtain the transformants. Plasmid DNAs were prepared from the transformants, and restriction maps were prepared. One having the same restriction map as that of Fig. 2 was designated as pSFK6. This plasmid is auto-

mously replicable in both of *Escherichia coli* and coryneform bacteria, and imparts kanamycin resistance to a host.

<3> Construction of a plasmid having temperature sensitive replication control region

- 5 [0049] pSFK6 was treated with hydroxylamine *in vitro*. The hydroxylamine treatment was performed according to a known method [see, for example, G.O. Humpherys, *et al.*, *Molec. Gen. Genet.*, 145, 101-108 (1976)]. DNA undergone the treatment was collected and used for transformation of *Brevibacterium lactofermentum* ATCC13869 strain. The transformants were selected at a low temperature (25°C) on a CM2B plate containing 25 µg/ml of kanamycin. The appeared transformants were replicated to a similar selection plate, and cultured at an elevated temperature (34°C).
10 One strain that could not grow on the selection plate containing kanamycin at the elevated temperature was obtained. From this strain, a plasmid was recovered and designated as p48K.

<4> Determination of nucleotide sequence of temperature sensitive replication control region

- 15 [0050] Nucleotide sequences of replication control region segments in the plasmid pSFK6 having a wild-type replication control region and the plasmid p48K having a temperature sensitive replication control region were determined. The nucleotide sequences were determined on a fully automatic sequencer, ABI310 (ABI), by using DNA Sequencing Kit from ABI. As a result, it was found that there were 6 nucleotide substitutions between the wild-type replication control region and the temperature sensitive replication control region. The nucleotide sequence of the temperature sensitive replication control region segment contained in pSFK6 (derived from full sequence of pAM330), which functions in coryneform bacteria, is shown in SEQ ID NO: 5, and the nucleotide sequence of the temperature sensitive replication control region segment contained in p48K, which functions in coryneform bacteria, is shown in SEQ ID NO: 7. Further, the amino acid sequences encoded by ORFs contained in these nucleotide sequences are shown in SEQ ID NOS: 6 and 8. In the temperature sensitive replication control region, the 1255th C is mutated to T, the 1534th C to T, the 1866th G to A, the 2058th G to A, the 2187th C to T and 3193rd G to A. Among these, only the mutation at 1534th position is accompanied by an amino acid mutation, and causes substitution of serine for proline.
20
25

<5> Construction of shuttle vectors having temperature sensitive mutation

- 30 [0051] Each one of the six mutations of p48K was introduced into a shuttle vector pSFK6 (see Fig. 3). The introduction of the mutations was performed by a known method [Mikaelian, I., Sergeant, A., *Nucleic Acids Res.*, 20, 376 (1992)]. Specific procedure will be mentioned below. In order to introduce the mutation of 1534th C to T, PCR was performed by using a combination of the primers shown in SEQ ID NOS: 9 and 10 (primers 9 and 10), and a combination of the primers shown in SEQ ID NOS: 11 and 12 (primers 11 and 12), and pAM330 as a template. Each of the obtained amplification products was purified by subjecting them to agarose gel electrophoresis, and collecting them from the gel. The collection of the DNA fragments from the gel was performed by using EASYTRAP Ver.2 (Takara Shuzo Co., Ltd.). The purified DNAs were mixed in a molar ratio of 1:1, and used as a template for PCR performed by using the primers shown SEQ ID NOS: 13 and 14 (primers 13 and 14). The amplification product was fully digested with a restriction enzyme MluI, and subjected to agarose gel electrophoresis to recover a DNA fragment of about 3.2 kb.
35
40 Similarly, pSFK6 was also completely digested with a restriction enzyme MluI, and subjected to agarose gel electrophoresis to recover a DNA fragment of about 3.8 kb. The obtained DNA fragments were mixed and ligated, and used to transform competent cells of *Escherichia coli* JM109 (Takara Shuzo Co., Ltd.). The cells were applied on L medium containing 25 µg/ml of kanamycin, and cultured overnight. The appeared colonies were picked up, and isolated single colonies to obtain transformant strains. A plasmid was prepared from the transformant strains by the alkaline method, and the nucleotide sequence of the plasmid was determined to confirm that 1534th C in the sequence shown in SEQ ID NO: 5 was mutated to T. This plasmid was designated as pSFKT2 (Fig. 3).
45

Example 2: Cloning of *argR* gene and amplification effect thereof in coryneform bacteria

- 50 [0052] PCR was performed by using chromosome DNA of the *Brevibacterium flavum* wild strain 2247 (AJ14067) as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 15 (sequence of the nucleotide numbers 1717-1741 in SEQ ID NO: 17) and SEQ ID NO: 16 (sequence complementary to the sequence of the nucleotide numbers 2386-2362 in SEQ ID NO: 17) as primers (Primers 15 and 16). PCR was performed for 30 cycles with each cycle consisting of reactions at 98°C for 10 seconds, 58°C for 1 minute and 72°C for 3 minutes by using Pyrobest DNA polymerase (Takara Shuzo Co., Ltd.). The obtained amplified fragment was inserted into the *Sma*I site of the shuttle vector pSFK6 obtained in Example 1 to obtain plasmid pWR autonomously replicable in coryneform bacteria.
55

[0053] In order to investigate the amplification effect of *argR* gene in L-arginine producing coryneform bacteria, pWR

was introduced into the AJ113455 strain (FERM BP-6894), which is an L-arginine producer of *Brevibacterium flavum*. The plasmid was introduced by the electric pulse method (Japanese Patent Laid-open No. 2-207791). A transformant was selected as a kanamycin resistant strain on CM2G agar medium (containing 5 g of glucose, 5 g of NaCl and 15 g of agar in 1 L of pure water, pH 7.2) containing 25 μ g/ml of kanamycin to obtain AJ11345/pWR. As a control, pSFK6 was similarly introduced into the AJ113455 strain to obtain a transformant AJ11345/pSFK6.

[0054] Each of the aforementioned strains was plated on an agar medium containing 0.5 g/dl of glucose, 1 g/dl of polypeptone, 1 g/dl of yeast extract and 0.5 g/dl of NaCl, and cultured at 31.5°C for 20 hours. One platinum loop of the obtained cells were inoculated into a medium containing 4 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.1 g/dl of KH_2PO_4 , 0.04 g/dl of MgSO_4 , 0.001 g/dl of FeSO_4 , 0.001 g/dl of MnSO_4 , 5 μ g/dl of vitamin B₁, 5 μ g/dl of biotin and soybean protein hydrolysate (45 mg/dl as N amount), and cultured in a flask at 31.5°C for 50 hours with shaking. Accumulation amount of L-arginine (concentration, g/dl) in each culture broth was measured. The results are shown in Table 1. As a result, the *argR*-amplified strain hardly accumulated L-arginine. This demonstrated that the *argR* gene product functioned as an arginine repressor.

Table 1

Strain	L-Arginine accumulation amount (g/dl)
AJ11345/pSFK6	1.3
AJ11345/pWR	0.2

[0055] The result of nucleotide sequencing for the inserted fragment cloned in pWR is shown in SEQ ID NO: 17. An amino acid sequence that may be encoded by that nucleotide sequence is shown in SEQ ID NO: 18.

Example 3: Construction of *argR*-disrupted strain of coryneform bacterium and effect of deletion of arginine repressor

<1> Construction of plasmid for *argR* disruption

[0056] PCR was performed by using chromosome DNA of a wild strain of *Brevibacterium flavum*, 2247 strain (AJ14067), as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 19 (sequence of the nucleotide numbers 4-28 in SEQ ID NO: 17) and SEQ ID NO: 20 (sequence complementary to the sequence of the nucleotide numbers 4230-4211 in SEQ ID NO: 17) as primers (Primers 19 and 20). PCR was performed for 30 cycles with each cycle consisting of reactions at 98°C for 10 seconds, 58°C for 1 minute and 72°C for 3 minutes by using Pyrobest DNA polymerase (Takara Shuzo Co., Ltd.). The obtained amplified fragment was inserted into the *Sma*I site in a multicloning site of cloning vector pHSG399.

[0057] In order to delete the whole ORF considered to encode the arginine repressor from the inserted DNA fragment, PCR was performed by using the oligonucleotides having the nucleotide sequences shown in SEQ ID NO: 21 (sequence of the nucleotide numbers 2372-2395 in SEQ ID NO: 17) and SEQ ID NO: 22 (sequence complementary to the sequence of the nucleotide numbers 1851-1827 in SEQ ID NO: 17) as primers (Primers 21 and 22) and pHSG399 inserted with the amplified fragment as a template. pssER was constructed by self-ligation of the PCR product.

[0058] Then, a fragment obtained by digesting pssER with restriction enzymes *Sma*I and *Sa*I and the temperature sensitive plasmid pSFKT2 obtained in Example 1 and digested with *Sma*I and *Sa*I were ligated to obtain plasmid pssERT for *argR* disruption whose autonomous replication ability in coryneform bacteria became temperature sensitive.

<2> Construction of arginine repressor deficient strain of coryneform bacterium by homologous recombination

[0059] The plasmid pssERT obtained as described above was introduced into the *Brevibacterium lactofermentum* AJ13029 strain (FERM BP-5189). The plasmid was introduced by the electric pulse method (Japanese Patent Laid-open No. 2-207791). Because autonomous replication ability of this plasmid is temperature sensitive in *Brevibacterium lactofermentum*, only strains in which this plasmid was incorporated into the chromosome by homologous recombination could be selected as kanamycin resistant strains at 34°C, which was a temperature that did not allow replication of the plasmid. Strains in which the plasmid for *argR* disruption was incorporated into a chromosome were selected as kanamycin resistant strains on a CM2G plate (containing 10 g/L of polypeptone, 10 g/L of yeast extract, 5 g/L of glucose, 5 g/L of NaCl and 15 g/L of agar in 1 L of water, pH 7.2) containing 25 μ g/ml of kanamycin. At this stage, the normal *argR* gene derived from the chromosome and the *argR* gene derived from the plasmid in which ORF was deleted were present in tandem at the both sides of the plasmid portion on the chromosome.

[0060] Then, the recombinant strains were allowed to cause homologous recombination again, and strains that became kanamycin sensitive at 34°C, which was a temperature that did not allow the plasmid replication, were selected

as strains in which one of the *argR* genes was deleted. These strains include strains in which the normal *argR* gene remained on the chromosome and strains in which the disrupted *argR* gene remained on the chromosome. From these strains, a strain having only the disrupted *argR* gene was selected. An *argR* gene on the chromosome is determined to be the disrupted type by preparing chromosome of a strain that became kanamycin sensitive at 34°C, performing PCR utilizing the chromosome as a template and the oligonucleotides having the nucleotide sequences shown in SEQ ID NOS: 19 and 20 as primers (Primers 19 and 20), and confirming that the PCR product was shorter by about 600 bp than that obtained by similarly performing PCR utilizing chromosome derived from the parent strain as a template. [0061] Direct sequencing of the PCR product of the *argR*-disrupted strain selected as described above was performed to confirm that the *argR* gene was disrupted as desired, and thus AJ13029AR strain was obtained.

<3> Production of L-arginine with *argR*-disrupted strain

[0062] The AJ13029ΔR strain was plated on an agar medium containing 0.5 g/dl of glucose, 1 g/dl of polypeptone, 1 g/dl of yeast extract and 0.5 g/dl of NaCl, and cultured at 31.5°C for 20 hours. One platinum loop of the obtained cells were inoculated into a medium containing 3 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.1 g/dl of KH₂PO₄, 0.04 g/dl of MgSO₄, 0.001 g/dl of FeSO₄, 0.001 g/dl of MnSO₄, 300 μg/dl of vitamin B₁, 200 μg/dl of biotin and soybean protein hydrolysate (165 mg/dl as N amount) and adjusted to pH 7.0 with NaOH, and cultured at 31.5°C for 24 hours as seed culture.

[0063] The above seed culture broth was inoculated in an amount of 1 ml into a medium containing 4 g/dl of glucose, 6.5 g/dl of ammonium sulfate, 0.5 g/dl of KH₂PO₄, 0.04 g/dl of MgSO₄, 0.001 g/dl of FeSO₄, 0.01 g/dl of MnSO₄, 5 μg/dl of vitamin B₁, 5 μg/dl of biotin and soybean protein hydrolysate (45 mg/dl as N amount) and adjusted to pH 7.0 with KOH, and cultured in a flask at 31.5°C for 50 hours with shaking. Accumulation amount of L-arginine (concentration, mg/dl) in culture broth of each strain was measured. The results are shown in Table 2. As a result, the *argR*-disrupted strain accumulated L-arginine in a markedly larger amount compared with the parent strain.

Table 2

Strain	L-Arginine accumulation amount (mg/dl)
AJ13029	20
AJ13029ΔR	120

(Explanation of Sequence Listing)

[0064]

SEQ ID NO: 1: primer for amplification of kanamycin resistance gene of *Streptococcus faecalis*
 SEQ ID NO: 2: primer for amplification of kanamycin resistance gene of *Streptococcus faecalis*
 SEQ ID NO: 3: primer for amplification of vector portion of pHSG399
 SEQ ID NO: 4: primer for amplification of vector portion of pHSG399
 SEQ ID NO: 5: nucleotide sequence of replication control region of pSFK6
 SEQ ID NO: 6: amino acid sequence that may be encoded by ORF in pSFK6
 SEQ ID NO: 7: nucleotide sequence of replication control region of p48K
 SEQ ID NO: 8: amino acid sequence that may be encoded by ORF in p48K
 SEQ ID NO: 9: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6
 SEQ ID NO: 10: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6
 SEQ ID NO: 11: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6
 SEQ ID NO: 12: primer for 1st PCR for introducing mutation of 1534th C to T into pSFK6
 SEQ ID NO: 13: primer for 2nd PCR for introducing mutation of 1534th C to T into pSFK6
 SEQ ID NO: 14: primer for 2nd PCR for introducing mutation of 1534th C to T into pSFK6
 SEQ ID NO: 15: primer for *argR* gene amplification
 SEQ ID NO: 16: primer for *argR* gene amplification
 SEQ ID NO: 17: nucleotide sequence of DNA fragment containing *argR* gene
 SEQ ID NO: 18: amino acid sequence that may be encoded by the above DNA fragment
 SEQ ID NO: 19: primer for *argR* gene amplification
 SEQ ID NO: 20: primer for *argR* gene amplification
 SEQ ID NO: 21: primer for amplifying portions other than *argR* gene ORF of plasmid containing *argR* gene
 SEQ ID NO: 22: primer for amplifying portions other than *argR* gene ORF of plasmid containing *argR* gene

SEQUENCE LISTING

5 <110> Ajinomoto Co., Inc.

10 <120> Arginine Repressor Deficient Stain of Coryneform Bacterium and
Method for Producing L-Arginine

<130> OP1018

15 <140>
<141> 2001-04-

20 <150> JP2000-129167
<151> 2000-04-28

25 <160> 22

<170> PatentIn Ver. 2.0

30 <210> 1
<211> 32
<212> DNA
<213> Artificial Sequence

35 <220>
<223> Description of Artificial Sequence:primer for
40 amplifying kanamycin resistant gene of
Streptococcus faecalis

<400> 1
45 cccgttaact gcttgaaacc caggacaata ac 32

50

55

5
 <210> 2
 <211> 30
 <212> DNA
 <213> Artificial Sequence

10
 <220>
 <223> Description of Artificial Sequence:primer for
 amplifying kanamycin resistant gene of
 Streptococcus faecalis

15
 <400> 2
 cccgtaaca tgtacttcag aaaagattag 30

20
 <210> 3
 <211> 26
 <212> DNA
 <213> Artificial Sequence

25
 <220>
 <223> Description of Artificial Sequence:primer for
 amplifying Escherichia coli cloning vector pHSG399

30
 <400> 3
 gatattctacg tgccgatcaa cgtctc 26

35
 <210> 4
 <211> 25
 <212> DNA
 <213> Artificial Sequence

40
 <220>
 <223> Description of Artificial Sequence:primer for
 amplifying Escherichia coli cloning vector pHSG399

45
 <400> 4
 aggccttttt ttaaggcagt tattg 25

50
 <210> 5
 <211> 4447
 <212> DNA

55
 <213> Brevibacterium lactofermentum

<220>

<221> CDS

<222> (1318)..(2598)

<400> 5

5
 10
 15
 20
 25
 30
 35
 40
 45
 50
 55

aagcttgtct acgtctgatg ctttgaatcg gacggacttg ccgatcttgt atgcggtgat 60
 ttttccctcg tttgccact ttttaatggt ggccggggtg agagctacgc gggcggcgac 120
 ctgctgcgct gtgatccaat attcggggtc gttcactggt tcccctttct gatttctggc 180
 atagaagaac ccccgatgaac tgtgtgggtc cgggggttgc tgatttttgc gagacttctc 240
 gcgcaattcc ctagcttagg tgaaaacacc atgaaacact agggaaacac ccatgaaaca 300
 cccattaggg cagtagggcg gcttcttctg ctagggcttg catttgggcg gtgatctggt 360
 ctttagcgtg tgaaagtgtg tcgtagggtg cgtgctcaat gcactcgaac gtcacgtcat 420
 ttaccgggtc acggtagggc aagagaacta gtgggttaga cattgttttc ctggttgctg 480
 gtggtggtga gcttttctag ccgctcggtg aacgcggcga tcatgaactc ttggagggtt 540
 tcaccgttct gcattgcctg gcgcttcatt tcctcacgta gtgcaaagg aacgcgtgcg 600
 gtgaccacga cgggcttagc ctttgccctg gcttctagt cttcgatggt ggcttgtgcc 660
 tgcgcttctg gcgctgttag tgccgttga gcttcttga gttgctgttc tagctgtgcc 720
 ttggttgcca tgctttaaga ctctagtagc tttcctgcga tatgtcatgc gcattgcgtg 780
 caaacattgt cctgcaactc attcattatg tgcagtgtc ctgttactag tcgtacatac 840
 tcataattac ctagtctgca tgcagtgcatt gcacatgcag tcatgtcgtg ctaatgtgta 900
 aaacatgtac atgcagattg ctgggggtgc agggggcgga gccacctgt ccatgcgggg 960
 tgtggggctt gcccgcggg tacagacagt gagcaccggg gcacctagtc gcggataccc 1020
 cccctaggta tcggacacgt aaccctccca tgcgatgca aatctttaac attgagtacg 1080
 ggtaagctgg cagcatagc caagctaggc ggccaccaa caccactaaa aattaatagt 1140
 ccctagacaa gacaaacccc cgtgcgagct accaactcat atgcacgggg gccacataac 1200
 ccgaaggggt ttcaattgac aaccatagca ctagctaaga caacgggcac aacaccgcga 1260
 caaactcgca ctgcgaacc ccgcacaaca tcgggtctag gtaacactga aatagaa 1317
 gtg aac acc tct aag gaa ccg cag gtc aat gag ggt tct aag gtc act 1365
 Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
 1 5 10 15
 cgc gct agg gcg tgg cgt agg caa aac gtc atg tac aag atc acc aat 1413
 Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
 20 25 30
 agt aag gct ctg gcg ggg tgc cat agg tgg cgc agg gac gaa gct gtt 1461
 Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
 35 40 45
 gcg gtg tcc tgg tgc tct aac ggt gct tcg cag ttt gag ggt ctg caa 1509
 Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
 50 55 60
 aac tct cac tct cgc tgg ggg tca cct ctg gct gaa ttg gaa gtc atg 1557

EP 1 154 020 A2

	Asn	Ser	His	Ser	Arg	Trp	Gly	Ser	Pro	Leu	Ala	Glu	Leu	Glu	Val	Met	
	65					70					75					80	
5	ggc	gaa	cgc	cgc	att	gag	ctg	gct	att	gct	act	aag	aat	cac	ttg	gcg	1605
	Gly	Glu	Arg	Arg	Ile	Glu	Leu	Ala	Ile	Ala	Thr	Lys	Asn	His	Leu	Ala	
					85					90					95		
	gcg	ggt	ggc	gcg	ctc	atg	atg	ttt	gtg	ggc	act	ggt	cga	cac	aac	cgc	1653
10	Ala	Gly	Gly	Ala	Leu	Met	Met	Phe	Val	Gly	Thr	Val	Arg	His	Asn	Arg	
				100					105						110		
	tca	cag	tca	ttt	gcg	cag	gtt	gaa	gcg	ggt	att	aag	act	gcg	tac	tct	1701
	Ser	Gln	Ser	Phe	Ala	Gln	Val	Glu	Ala	Gly	Ile	Lys	Thr	Ala	Tyr	Ser	
15				115				120					125				
	tcg	atg	gtg	aaa	aca	tct	cag	tgg	aag	aaa	gaa	cgt	gca	cgg	tac	ggg	1749
	Ser	Met	Val	Lys	Thr	Ser	Gln	Trp	Lys	Lys	Glu	Arg	Ala	Arg	Tyr	Gly	
		130					135				140						
20	gtg	gag	cac	acc	tat	agt	gac	tat	gag	gtc	aca	gac	tct	tgg	gcg	aac	1797
	Val	Glu	His	Thr	Tyr	Ser	Asp	Tyr	Glu	Val	Thr	Asp	Ser	Trp	Ala	Asn	
	145					150				155					160		
25	ggt	tgg	cac	ttg	cac	cgc	aac	atg	ctg	ttg	ttc	ttg	gat	cgt	cca	ctg	1845
	Gly	Trp	His	Leu	His	Arg	Asn	Met	Leu	Leu	Phe	Leu	Asp	Arg	Pro	Leu	
					165				170				175				
	tct	gac	gat	gaa	ctc	aag	gcg	ttt	gag	gat	tcc	atg	ttt	tcc	cgc	tgg	1893
30	Ser	Asp	Asp	Glu	Leu	Lys	Ala	Phe	Glu	Asp	Ser	Met	Phe	Ser	Arg	Trp	
				180					185				190				
	tct	gct	ggt	gtg	gtt	aag	gcc	ggt	atg	gac	gcg	cca	ctg	cgt	gag	cac	1941
	Ser	Ala	Gly	Val	Val	Lys	Ala	Gly	Met	Asp	Ala	Pro	Leu	Arg	Glu	His	
35			195				200					205					
	ggg	gtc	aaa	ctt	gat	cag	gtg	tct	acc	tgg	ggt	gga	gac	gct	gcg	aaa	1989
	Gly	Val	Lys	Leu	Asp	Gln	Val	Ser	Thr	Trp	Gly	Gly	Asp	Ala	Ala	Lys	
		210				215					220						
40	atg	gca	acc	tac	ctc	gct	aag	ggc	atg	tct	cag	gaa	ctg	act	ggc	tcc	2037
	Met	Ala	Thr	Tyr	Leu	Ala	Lys	Gly	Met	Ser	Gln	Glu	Leu	Thr	Gly	Ser	
	225					230					235				240		
45	gct	act	aaa	acc	gcg	tct	aag	ggg	tcg	tac	acg	ccg	ttt	cag	atg	ttg	2085
	Ala	Thr	Lys	Thr	Ala	Ser	Lys	Gly	Ser	Tyr	Thr	Pro	Phe	Gln	Met	Leu	
				245					250					255			
	gat	atg	ttg	gcc	gat	caa	agc	gac	gcc	ggc	gag	gat	atg	gac	gct	gtt	2133
50	Asp	Met	Leu	Ala	Asp	Gln	Ser	Asp	Ala	Gly	Glu	Asp	Met	Asp	Ala	Val	

EP 1 154 020 A2

	tcg tcc tgg tca cgt ggg gct aag cgt gct ttg ggc att gat tac ata	2229
	Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile	
5	290 295 300	
	gac gct gat gta cgt cgt gaa atg gaa gaa gaa ctg tac aag ctc gcc	2277
	Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala	
	305 310 315 320	
10	ggt ctg gaa gca ccg gaa cgg gtc gaa tca acc cgc gtt gct gtt gct	2325
	Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala	
	325 330 335	
15	ttg gtg aag ccc gat gat tgg aaa ctg att cag tct gat ttc gcg gtt	2373
	Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val	
	340 345 350	
20	agg cag tac gtt cta gat tgc gtg gat aag gct aag gac gtg gcc gct	2421
	Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala	
	355 360 365	
	gcg caa cgt gtc gct aat gag gtg ctg gca agt ctg ggt gtg gat tcc	2469
	Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser	
25	370 375 380	
	acc ccg tgc atg atc gtt atg gat gat gtg gac ttg gac gcg gtt ctg	2517
	Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu	
	385 390 395 400	
30	cct act cat ggg gac gct act aag cgt gat ctg aat gcg gcg gtg ttc	2565
	Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe	
	405 410 415	
35	gcg ggt aat gag cag act att ctt cgc acc cac taaaagcggc ataaaccccg	2618
	Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His	
	420 425	
40	ttcgatattt tgtgcgatga atttatggtc aatgtcgcgg gggcaaacta tgatgggtct	2678
	tgttgttgac aatggctgat ttcattcagga atggaactgt catgctgtta tgtgcctggc	2738
	tcctaatacaa agctggggac aatgggttgc cccgttgatc tgatctagtt cggattggcg	2798
	gggcttcact gtatctgggg gtggcatcgt gaatagattg cacaccgtag tgggcagtgt	2858
	gcacaccata gtgggcatga gtaataccta cgcgcgcgtg ggctagggct taacgcgcgt	2918
45	tttgccgtgc tgcggggcat acgttagcgc atacgctttt ttctgtgaaa cctttttgtg	2978
	ttgtttgttc gtgttggttt cctttctgtt ggcggggcaa cttaacgcct gcgggggttg	3038
	ttgttgacgt taacgggggt agtttttatt cccctagtgg tttttagta cgacaatcga	3098
50	gaaagacctg tttcagccag ttcgggtcat gtctgtcggg atggccacgt gcatagcgac	3158
	cagttttcga gttcactggg atttttgtg catcgaacaa gatgtaggac aatgcggttt	3218
	ctaggtctac tttttgcttt atgccgtaca agccccgtgg gtattcagcg attgattcca	3278
	aggcggcttc ccagtcctgt tttgtgaagg actggcttag ttctaggtct gtgtctgggt	3338
	agtactgett gtttgtgtaa gcgccgttg tgctcattga tgattccttt gaagtgtttg	3398
55	gagttcggct agtagtgcgg cgtatgggtc tgctttttgc tcgtgatagc tcgccttgge	3458

tatgaggtcg gctaggtagg tticcggggt gcctaggttg cgtaggtcta gcaaatcccg 3518
 gtatgtggcc tgtgcgctgc gctgggtggc catacagtcg ttaagctggg cttttacgtc 3578
 5 tgcgatgcgg tggcggtag gcatgttggt gtgtctcttc caagtactca cgggcgggtt 3638
 ttgtgtatgc ctggcgtgat gcttctttga gctgttggag ttccgcttgg agtgcgggta 3698
 gttcgtccgc gaactgcttg tggtagctgt atttctcttg ttcttgggag atagcatttg 3758
 cgttgaattg cagggcgggt agttcgtcca cgcgtcgttt tgctgcgttg gtcattggtg 3818
 10 cgtgccattt gcggttggg acgcgggggt caaggttgcg cacggctgct tcggctaggt 3878
 tgggtgctgc ttttttcagt gctcgggctt cccgttcttc gtccaacgag agcacctttg 3938
 gtttgttggc ttccgctagt ttttgcttct ccgctttgat gagtttgtca acttcgtgtt 3998
 gggagaggtc gtttttcacg atgcgtcgaa tgtggctggt gtgggtgctg agttggtgtg 4058
 15 agaggtagtg gggttctggg atttcggcga gttggctgag gttggtgtag tgcgggttgc 4118
 ggcttggttg gttgggttcg ctggggaggt cgatgtatcc ggttgagtct ccggcgtggt 4178
 tgaagtgaat taggcgttgg tagccgtatt cctgggtggg gaggtacgac agaattgagga 4238
 agtttgggtc ttctcctgca atgagtcgtg cgtgttcgtg gttcgggtact ggtcgtgct 4298
 20 cggggagaaat gttcttttgg gtcattgctt ctctttctgt tgctctgtaa gtccgtatgt 4358
 gggcatggga aagccccggc aacccttttg gtcaaccggg gctagatagt cgcttagaat 4418
 ggcttctagg ctgcgtctcg ggtgtggc 4447

25

<210> 6

<211> 427

<212> PRT

30

<213> Brevibacterium lactofermentum

<400> 6

35

Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr

1 5 10 15

Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn

20 25 30

40

Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val

35 40 45

Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln

50 55 60

45

Asn Ser His Ser Arg Trp Gly Ser Pro Leu Ala Glu Leu Glu Val Met

65 70 75 80

Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala

85 90 95

50

Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg

100 105 110

Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser

115 120 125

55

Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly

EP 1 154 020 A2

	130	135	140
	Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn		
5	145	150	155 160
	Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu		
	165	170	175
10	Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp		
	180	185	190
	Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His		
	195	200	205
15	Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys		
	210	215	220
	Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser		
	225	230	235 240
20	Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu		
	245	250	255
	Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val		
	260	265	270
25	Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg		
	275	280	285
	Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile		
	290	295	300
30	Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala		
	305	310	315 320
	Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala		
	325	330	335
35	Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val		
	340	345	350
	Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala		
	355	360	365
40	Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser		
	370	375	380
	Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu		
45	385	390	395 400
	Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe		
	405	410	415
	Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His		
50	420	425	

<210> 7

<211> 4447

55

<212> DNA

<213> Brevibacterium lactofermentum

5

<220>

<221> CDS

<222> (1318)..(2598)

10

<400> 7

15

20

25

30

35

40

45

50

55

```

aagcttgctt acgtctgatg ctttgaatcg gacggacttg ccgatcttgt atgcggtgat 60
ttttccctcg ttgcccact ttttaatggt ggccgggggtg agagctacgc gggcggcgac 120
ctgctgcgct gtgatccaat attcggggtc gttcactggt tcccctttct gatttctggc 180
atagaagaac ccccgatgaac tgtgtgggtc cgggggttgc tgatttttgc gagacttctc 240
gcgcaattcc ctagcttagg tgaaaacacc atgaaacact agggaaacac ccatgaaaca 300
cccattaggg cagtagggcg gcttcttcgt ctagggcttg catttgggcg gtgatctggt 360
cttttagcgtg tgaaagtgtg tcgtaggtgg cgtgctcaat gcactcgaac gtcacgtcat 420
ttaccgggtc acgggtggca aagagaacta gtgggttaga cattgtttc ctcgttgctg 480
gtggtggtga gcttttctag ccgctcggta aacgcggcga tcatgaactc ttggaggttt 540
tcaccgttct gcctgcctgc gcgcttcctg tcctcagta gtgccaaagg aacgcgtgcg 600
gtgaccacga cgggcttagc ctttgcctgc gcttctagtg cttecatggt ggcttctgcc 660
tgcgcttgct gcgcctgtag tgccgttga gcttcttgta gttgctgttc tagctgtgcc 720
ttggttgcca tgctttaaga ctctagtagc ttctctgca tatgtcatgc gcctgcgtag 780
caaacattgt cctgcaactc attcattatg tgcagtgtc ctgttactag tcgtacatac 840
tcatatttac ctagtctgca tgcagtgcct gcacatgcag tcatgtcgtg ctaatgtgta 900
aaacatgtac atgcagattg ctgggggtgc agggggcgga gccaccctgt ccatgcgggg 960
tgtggggctt gcccgcggg tacagacagt gagcaccggg gcacctagtc gcggataccc 1020
cccctaggta teggacacgt aaccctccca tgcgatgca aatctttaac attgagtacg 1080
ggtaagctgg cagcatagc caagctaggg ggccacaaa caccactaaa aattaatagt 1140
tcctagacaa gacaaacccc cgtgcgagct accaactcat atgcacgggg gccacataac 1200
ccgaaggggt ticaattgac aaccatagca ctagctaaga caacgggcac aacatccgca 1260
caaactgca ctgcgcaacc ccgcacaaca tcgggtctag gtaacactga aatagaa 1317
gtg aac acc tct aag gaa ccg cag gtc aat gag ggt tct aag gtc act 1365
Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
      1           5           10           15
cgc gct agg gcg tgg cgt agg caa aac gtc atg tac aag atc acc aat 1413
Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
      20           25           30
agt aag gct ctg gcg ggg tgc cat agg tgg cgc agg gac gaa gct gtt 1461
Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
      35           40           45
gcg gtg tcc tgg tgc tct aac ggt gct tgc cag ttt gag ggt ctg caa 1509
Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
      50           55           60

```

EP 1 154 020 A2

	aac tct cac tct cgc tgg ggg tca tct ctg gct gaa ttg gaa gtc atg	1557
	Asn Ser His Ser Arg Trp Gly Ser Ser Leu Ala Glu Leu Glu Val Met	
5	65 70 75 80	
	ggc gaa cgc cgc att gag ctg gct att gct act aag aat cac ttg gcg	1605
	Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala	
	85 90 95	
10	gcg ggt ggc gcg ctc atg atg ttt gtg ggc act gtt cga cac aac cgc	1653
	Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg	
	100 105 110	
15	tca cag tca ttt gcg cag gtt gaa gcg ggt att aag act gcg tac tct	1701
	Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser	
	115 120 125	
20	tcg atg gtg aaa aca tct cag tgg aag aaa gaa cgt gca cgg tac ggg	1749
	Ser Met Val Lys Thr Ser Gln Trp Lys Lys Glu Arg Ala Arg Tyr Gly	
	130 135 140	
25	gtg gag cac acc tat agt gac tat gag gtc aca gac tct tgg gcg aac	1797
	Val Glu His Thr Tyr Ser Asp Tyr Glu Val Thr Asp Ser Trp Ala Asn	
	145 150 155 160	
	ggt tgg cac ttg cac cgc aac atg ctg ttg ttc ttg gat cgt cca ctg	1845
	Gly Trp His Leu His Arg Asn Met Leu Leu Phe Leu Asp Arg Pro Leu	
	165 170 175	
30	tct gac gat gaa ctc aag gca ttt gag gat tcc atg ttt tcc cgc tgg	1893
	Ser Asp Asp Glu Leu Lys Ala Phe Glu Asp Ser Met Phe Ser Arg Trp	
	180 185 190	
35	tct gct ggt gtg gtt aag gcc ggt atg gac gcg cca ctg cgt gag cac	1941
	Ser Ala Gly Val Val Lys Ala Gly Met Asp Ala Pro Leu Arg Glu His	
	195 200 205	
40	ggg gtc aaa ctt gat cag gtg tct acc tgg ggt gga gac gct gcg aaa	1989
	Gly Val Lys Leu Asp Gln Val Ser Thr Trp Gly Gly Asp Ala Ala Lys	
	210 215 220	
45	atg gca acc tac ctc gct aag ggc atg tct cag gaa ctg act ggc tcc	2037
	Met Ala Thr Tyr Leu Ala Lys Gly Met Ser Gln Glu Leu Thr Gly Ser	
	225 230 235 240	
	gct act aaa acc gcg tct aaa ggg tcg tac acg ccg ttt cag atg ttg	2085
	Ala Thr Lys Thr Ala Ser Lys Gly Ser Tyr Thr Pro Phe Gln Met Leu	
	245 250 255	
50	gat atg ttg gcc gat caa agc gac gcc ggc gag gat atg gac gct gtt	2133
	Asp Met Leu Ala Asp Gln Ser Asp Ala Gly Glu Asp Met Asp Ala Val	
	260 265 270	
55	ttg gtg gct cgg tgg cgt gag tat gag gtt ggt tct aaa aac ctg cgt	2181
	Leu Val Ala Arg Trp Arg Glu Tyr Glu Val Gly Ser Lys Asn Leu Arg	

EP 1 154 020 A2

	275	280	285	
5	tcg tct tgg tca cgt ggg gct aag cgt gct ttg ggc att gat tac ata			2229
	Ser Ser Trp Ser Arg Gly Ala Lys Arg Ala Leu Gly Ile Asp Tyr Ile			
	290	295	300	
10	gac gct gat gta cgt cgt gaa atg gaa gaa gaa ctg tac aag ctc gcc			2277
	Asp Ala Asp Val Arg Arg Glu Met Glu Glu Glu Leu Tyr Lys Leu Ala			
	305	310	315	320
	ggt ctg gaa gca ccg gaa cgg gtc gaa tca acc cgc gtt gct gtt gct			2325
	Gly Leu Glu Ala Pro Glu Arg Val Glu Ser Thr Arg Val Ala Val Ala			
	325	330	335	
15	ttg gtg aag ccc gat gat tgg aaa ctg att cag tct gat ttc gcg gtt			2373
	Leu Val Lys Pro Asp Asp Trp Lys Leu Ile Gln Ser Asp Phe Ala Val			
	340	345	350	
20	agg cag tac gtt cta gat tgc gtg gat aag gct aag gac gtg gcc gct			2421
	Arg Gln Tyr Val Leu Asp Cys Val Asp Lys Ala Lys Asp Val Ala Ala			
	355	360	365	
25	gcg caa cgt gtc gct aat gag gtg ctg gca agt ctg ggt gtg gat tcc			2469
	Ala Gln Arg Val Ala Asn Glu Val Leu Ala Ser Leu Gly Val Asp Ser			
	370	375	380	
30	acc ccg tgc atg atc gtt atg gat gat gtg gac ttg gac gcg gtt ctg			2517
	Thr Pro Cys Met Ile Val Met Asp Asp Val Asp Leu Asp Ala Val Leu			
	385	390	395	400
	cct act cat ggg gac gct act aag cgt gat ctg aat gcg gcg gtg ttc			2565
	Pro Thr His Gly Asp Ala Thr Lys Arg Asp Leu Asn Ala Ala Val Phe			
	405	410	415	
35	gcg ggt aat gag cag act att ctt cgc acc cac taaaagcggc ataaaccccg			2618
	Ala Gly Asn Glu Gln Thr Ile Leu Arg Thr His			
	420	425		
40	ttcgatattt tgtgcgatga atttatggtc aatgtcgcgg gggcaaacta tgatgggtct			2678
	tgttggtgac aatggctgat ttcacagga atggaactgt catgctgtta tgtgcctggc			2738
	tcctaataca agctggggac aatgggttgc cccgttgatc tgatctagtt cggattggcg			2798
	gggcttcaact gtatctgggg gtggcatcgt gaatagattg cacaccgtag tgggcagtgt			2858
45	gcacaccata gtgggcatga gtaataccta cgcgcgcgtg ggctagggt taacgcgcgt			2918
	tttgccgtgc tgcggggcat acgttagcgc atacgctttt ttctgtgaaa cctttttgtg			2978
	ttgttgtttc gtgttggttt cctttctgtt ggcggggcaa cttaacgcct gcgggggtgg			3038
	ttgttgacgt taacgggggt agtttttatt cccctagtgg ttttcagta cgacaatcga			3098
50	gaaagacctg tttcagccag ttcgggtcat gtctgctggt atggccacgt gcatagcgac			3158
	cagttttcga gttcactggg atttttggtg catcaaaca gatgtaggac aatgcggttt			3218
	ctaggtctac tttttgcttt atgccgtaca agccccgtgg gtattcagcg attgattcca			3278
55	aggcggcttc ccagtcctgt tttgtgaagg actggcttag ttctaggtct gtgtctgggt			3338
	agtactgctt gtttgtgtaa gcgccgttg tgctcattga tgattccttt gaagtgtttg			3398

EP 1 154 020 A2

5 gagttcggct agtagtgccg cgtatggtgc tgctttttgc tcgtgatagc tcgccttggc 3458
 tatgaggtcg gctaggtagg ttccgggggt gcctaggttg cgtaggtcta gcaaattccg 3518
 gtatgtggcc tgtgcgctgc gctgggtgtg catacagtcg ttaagctggg cttttacgtc 3578
 tgcgatgcgg tggcggttag gcatgttggt gtgcttcttc caagtactca cgggcggggt 3638
 ttgtgtatgc ctggcgtgat gcttctttga gctgttggag ttccgcttgg agtgcgggta 3698
 gttcgtccgc gaactgcttg tggtagctgt atttctcttg ttcttgggag atagcatttg 3758
 10 cgttgaattg cagggcgggt agttcgtcca cgcgtcgttt tgetgcgttg gtcattggtg 3818
 cgtgccattt gcggttgttg acgcgggggt caaggttgcg cacggctgct tcggctaggt 3878
 tggtagctgc ttttttcagt gctcgggctt cccgttcctc gtccaacgag agcacctttg 3938
 gtttgttggc ttccgctagt ttttgcttct ccgctttgat gagttggtca acttcgtgtt 3998
 15 gggagaggtc gtttttcacg atgcgtcgaa tgtggtcgtt gtgggtgctg agttggtgtg 4058
 agaggtagtg gggttctggg atttcggcga gttggtcgag gttggtgtag tgcgggttgc 4118
 ggcctggttg gttgggttcg ctggggaggt cgatgtatcc ggttgagtct ccggcgtggt 4178
 20 tgaagtgaat taggcgttgg tagccgtatt cctggttggg gaggtacgac agaattgagga 4238
 agtttgggtc ttctcctgca atgagtcgtg cgtgttcgta gttcgggtact gggtcgtgct 4298
 cggggagaat gttcttttgg gtcattgctt ctctttctgt tgctctgtaa gtccgtatgt 4358
 gggcatggga aagccccggc aacccttttg gtcaaccggg gctagatagt cgcttagaat 4418
 25 ggcttctagg ctgcgtctcg ggggtgtggc 4447

<210> 8
 <211> 427
 30 <212> PRT
 <213> Brevibacterium lactofermentum

 <400> 8
 35 Val Asn Thr Ser Lys Glu Pro Gln Val Asn Glu Gly Ser Lys Val Thr
 1 5 10 15
 Arg Ala Arg Ala Trp Arg Arg Gln Asn Val Met Tyr Lys Ile Thr Asn
 20 25 30
 40 Ser Lys Ala Leu Ala Gly Cys His Arg Trp Arg Arg Asp Glu Ala Val
 35 40 45
 Ala Val Ser Trp Ser Ser Asn Gly Ala Ser Gln Phe Glu Gly Leu Gln
 45 50 55 60
 Asn Ser His Ser Arg Trp Gly Ser Ser Leu Ala Glu Leu Glu Val Met
 65 70 75 80
 Gly Glu Arg Arg Ile Glu Leu Ala Ile Ala Thr Lys Asn His Leu Ala
 50 85 90 95
 Ala Gly Gly Ala Leu Met Met Phe Val Gly Thr Val Arg His Asn Arg
 100 105 110
 55 Ser Gln Ser Phe Ala Gln Val Glu Ala Gly Ile Lys Thr Ala Tyr Ser
 115 120 125

EP 1 154 020 A2

	Ser	Met	Val	Lys	Thr	Ser	Gln	Trp	Lys	Lys	Glu	Arg	Ala	Arg	Tyr	Gly
	130						135					140				
5	Val	Glu	His	Thr	Tyr	Ser	Asp	Tyr	Glu	Val	Thr	Asp	Ser	Trp	Ala	Asn
	145					150					155				160	
	Gly	Trp	His	Leu	His	Arg	Asn	Met	Leu	Leu	Phe	Leu	Asp	Arg	Pro	Leu
				165						170					175	
10	Ser	Asp	Asp	Glu	Leu	Lys	Ala	Phe	Glu	Asp	Ser	Met	Phe	Ser	Arg	Trp
				180					185					190		
	Ser	Ala	Gly	Val	Val	Lys	Ala	Gly	Met	Asp	Ala	Pro	Leu	Arg	Glu	His
		195						200					205			
15	Gly	Val	Lys	Leu	Asp	Gln	Val	Ser	Thr	Trp	Gly	Gly	Asp	Ala	Ala	Lys
	210						215				220					
	Met	Ala	Thr	Tyr	Leu	Ala	Lys	Gly	Met	Ser	Gln	Glu	Leu	Thr	Gly	Ser
20	225					230				235					240	
	Ala	Thr	Lys	Thr	Ala	Ser	Lys	Gly	Ser	Tyr	Thr	Pro	Phe	Gln	Met	Leu
				245					250				255			
	Asp	Met	Leu	Ala	Asp	Gln	Ser	Asp	Ala	Gly	Glu	Asp	Met	Asp	Ala	Val
25		260					265				270					
	Leu	Val	Ala	Arg	Trp	Arg	Glu	Tyr	Glu	Val	Gly	Ser	Lys	Asn	Leu	Arg
		275					280				285					
	Ser	Ser	Trp	Ser	Arg	Gly	Ala	Lys	Arg	Ala	Leu	Gly	Ile	Asp	Tyr	Ile
30	290					295					300					
	Asp	Ala	Asp	Val	Arg	Arg	Glu	Met	Glu	Glu	Glu	Leu	Tyr	Lys	Leu	Ala
	305				310					315					320	
	Gly	Leu	Glu	Ala	Pro	Glu	Arg	Val	Glu	Ser	Thr	Arg	Val	Ala	Val	Ala
35				325					330				335			
	Leu	Val	Lys	Pro	Asp	Asp	Trp	Lys	Leu	Ile	Gln	Ser	Asp	Phe	Ala	Val
		340					345				350					
40	Arg	Gln	Tyr	Val	Leu	Asp	Cys	Val	Asp	Lys	Ala	Lys	Asp	Val	Ala	Ala
		355					360				365					
	Ala	Gln	Arg	Val	Ala	Asn	Glu	Val	Leu	Ala	Ser	Leu	Gly	Val	Asp	Ser
	370					375					380					
45	Thr	Pro	Cys	Met	Ile	Val	Met	Asp	Asp	Val	Asp	Leu	Asp	Ala	Val	Leu
	385					390					395				400	
	Pro	Thr	His	Gly	Asp	Ala	Thr	Lys	Arg	Asp	Leu	Asn	Ala	Ala	Val	Phe
				405					410				415			
50	Ala	Gly	Asn	Glu	Gln	Thr	Ile	Leu	Arg	Thr	His					
		420					425									
	<210>	9														
55	<211>	30														

5 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:primer for
 10 introducing mutation to pAM330
 <400> 9
 aaaccgggc tacgtctgat gctttgaate 30
 15 <210> 10
 <211> 27
 <212> DNA
 20 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:primer for
 25 introducing mutation to pAM330
 <400> 10
 ttgatcccc cgtaacgtc aacaacc 27
 30 <210> 11
 <211> 28
 <212> DNA
 35 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:primer for
 40 introducing mutation to pAM330
 <400> 11
 ttttccggg agcttgccac accccgag 28
 45 <210> 12
 <211> 24
 <212> DNA
 50 <213> Artificial Sequence
 <220>
 55 <223> Description of Artificial Sequence:primer for
 introducing mutation to pAM330

5	<p><400> 12 gggggtcatc tctggctgaa ttgg</p>	24
10	<p><210> 13 <211> 24 <212> DNA <213> Artificial Sequence</p>	
15	<p><220> <223> Description of Artificial Sequence:primer for introducing mutation to pAM330</p>	
20	<p><400> 13 gaggttttca ccgttctgca tgcc</p>	24
25	<p><210> 14 <211> 23 <212> DNA <213> Artificial Sequence</p>	
30	<p><220> <223> Description of Artificial Sequence:primer for introducing mutation to pAM330</p>	
35	<p><400> 14 aactcaccgc cctgcaattc aac</p>	23
40	<p><210> 15 <211> 25 <212> DNA <213> Artificial Sequence</p>	
45	<p><220> <223> Description of Artificial Sequence:primer for PCR</p>	
50	<p><400> 15 gcctaccgcg gcaaagaagt ggcag</p>	25
55	<p><210> 16 <211> 25</p>	

<212> DNA

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence: primer for PCR

10

<400> 16

gccttgaact agggcgctt taagt

25

<210> 17

15

<211> 4235

<212> DNA

<213> Brevibacterium flavum

20

<220>

<221> CDS

<222> (1852)..(2364)

25

<400> 17

aaacccgggt tttcttctgc aactcgggcg ccgaagcaaa cgaggctgct ttcaagattg 60
 cacgcttgac tggctgttcc cggattctgg ctgcagttca tggtttccac ggccgcacca 120
 tgggttccct cgcgctgact ggccagccag acaagcgtga agcgttccctg ccaatgccaa 180
 gcggtgtgga gttctaccct tacggcgaca ccgattactt gcgcaaaatg gtagaaacca 240
 acccaacgga tgtggctgct atcttctcgc agccaatcca gggtgaaacg ggcgttggtc 300
 cagcacctga aggattcttc aaggcagtgc gcgagctgtg cgatgagtac ggcattctga 360
 tgatcacga tgaagtccag actggcgttg gccgtaccgg cgatttcttt gcacatcagc 420
 acgatggcgt tgttcccgat gtggtgacca tggccaaggg acttggcggc ggtcttccca 480
 tcggtgcttg tttggccact ggccgtgcag ctgaattgat gacccaggc aagcacggca 540
 ccactttegg tggcaacca gttgcttgtg cagctgccaa ggcagtgtg tctgttgtcg 600
 atgacgcttt ctgcgcagaa gttaccgcga agggcgagct gttcaaggta cttcttgcca 660
 aggttgacgg cgttgtagac gtccgtggca gggcgttgat gttgggcgtg gtgctggagc 720
 gcgacgtcgc aaagcaagct gttcttgatg gttttaagca cggcgttatt ttgaatgcac 780
 cggcggacaa cattatcgt ttgacccgc cgctggatgat caccgacgaa gaaatcgag 840
 acgcagtcaa ggctattgcc gagacaatcg cataaaggac ttaaacttat gacttcacaa 900
 ccacaggctc gccatttctt ggctgatgat gatctaccc ctgcagagca ggcagagggt 960
 ttgaccctag ccgcaaagct caaggcagcg ccgttttcgg agcgtccact cgagggacca 1020
 aagtccgttg cagttctttt tgataagact tcaactcgta ctcgttctc cttcgacgag 1080
 ggcatcgctc atttgggttg acatgccatc gtcgtggatt ccggcagctc acagatgggt 1140
 aaggcgaga ccctgcagga caccgcagct gtattgtccc gctacgtgga agcaattgtg 1200
 tggcgacct acgcacacag caatttcac gccatggcgg agacgtccac tgtgccgctg 1260
 gtgaactcct tgtccgatga tctgcacca tgccagattc tggctgatct gcagaccatc 1320

55

EP 1 154 020 A2

gtggaaaacc tcagccctga agaaggccca gcaggcetta agggtaagaa ggctgtgtac 1380
ctgggcgatg gcgacaacaa catggccaac tcctacatga ttggctttgc caccgcgggc 1440
5 atggatatit ccatcatcgc tcctgaaggg ttccagcctc gtgcggaatt cgtggagcgc 1500
gcggaaaagc gtggccagga aaccggcgcg aaggttgtg tcaccgacag cctcgacgag 1560
gttgccggcg ccgatgtgt catcaecgat acctgggtat ccatgggtat ggaaaacgac 1620
ggcatcgatc gcaccacacc ttctgttctc taccaggtca acgatgaggt catggcgaaa 1680
10 gctaacgacg gcgccatctt cctgcactgc ctctctgcct accgcggcaa agaagtggca 1740
gcctccgtga ttgatggacc agcgtccaaa gttttcgatg aagcagaaaa ccgcctccac 1800
gctcagaaag cactgctggt gtggctgctg gccaccagc cgaggtaga c atg tct 1857
Met Ser
15
1
ctt ggc tca acc ccg tca aca ccg gaa aac tta aat ccc gtg act cgc 1905
Leu Gly Ser Thr Pro Ser Thr Pro Glu Asn Leu Asn Pro Val Thr Arg
5 10 15
20 act gca cgc caa gct ctc att ttg cag att ttg gac aaa caa aaa gtc 1953
Thr Ala Arg Gln Ala Leu Ile Leu Gln Ile Leu Asp Lys Gln Lys Val
20 25 30
25 acc agc cag gta caa ctg tct gaa ttg ctg ctg gat gaa ggc atc gat 2001
Thr Ser Gln Val Gln Leu Ser Glu Leu Leu Leu Asp Glu Gly Ile Asp
35 40 45 50
30 atc acc cag gcc acc ttg tcc cgg gat ctc gat gaa ctc ggt gca cgc 2049
Ile Thr Gln Ala Thr Leu Ser Arg Asp Leu Asp Glu Leu Gly Ala Arg
55 60 65
35 aag gtt cgc ccc gat ggg gga cgc gcc tac tac gcg gtc ggc cca gta 2097
Lys Val Arg Pro Asp Gly Gly Arg Ala Tyr Tyr Ala Val Gly Pro Val
70 75 80
gat agc atc gcc cgc gaa gat ctc cgg ggt ccg tcg gag aag ctg cgc 2145
Asp Ser Ile Ala Arg Glu Asp Leu Arg Gly Pro Ser Glu Lys Leu Arg
85 90 95
40 cgc atg ctt gat gaa ctg ctg gtt tct aca gat cat tcc ggc aac atc 2193
Arg Met Leu Asp Glu Leu Leu Val Ser Thr Asp His Ser Gly Asn Ile
100 105 110
45 gcg atg ctg cgc acc ccg ccg gga gct gcc cag tac ctg gca agt ttc 2241
Ala Met Leu Arg Thr Pro Pro Gly Ala Ala Gln Tyr Leu Ala Ser Phe
115 120 125 130
50 atc gat agg gtg ggg ctg aaa gaa gtc gtt ggc acc atc gct ggc gat 2289
Ile Asp Arg Val Gly Leu Lys Glu Val Val Gly Thr Ile Ala Gly Asp
135 140 145
gac acc gtt ttt gtt ctc gcc cgt gat ccg ctc aca ggt aaa gaa cta 2337
Asp Thr Val Phe Val Leu Ala Arg Asp Pro Leu Thr Gly Lys Glu Leu
55 150 155 160

EP 1 154 020 A2

ggt gaa tta etc agc ggg cgc acc act taaagcgccc ctagttcaag 2384
Gly Glu Leu Leu Ser Gly Arg Thr Thr

5

165

170

10

15

20

25

30

35

40

45

gcttgtaaat cgcttgtaa tgcaggcagg taaggtataa cccgagtgtt ttttcgagga 2444
ataccaaccc ttccaacaca ataattttct ttaaaccatcc ttgctgtcca ccacggctgg 2504
caaggaactt aaaatgaagg agcacacctc atgactaacc gcatcggttct tgcatactcc 2564
ggcggctctgg acaccactgt ggcaattcca tactgaaga agatgattga tggtaagtc 2624
atcgagttt ctctcgacct gggccagggt ggagagaaca tggacaacgt tcgccagcgt 2684
gcattggatg ccggtgcagc tgagtcacac gttgttgatg caaaggatga gtccgctgag 2744
gagtactgcc tgccaacat caaggcaaac ggcatgtaca tgaagcagta cccactggtt 2804
tctgcaatct cccgccaact gatcgtaag cactcgttg aggctggcaa gcagttcaac 2864
ggtaccacg ttgcacacgg ctgcaactgt aagggaacg accaggttcg tttcgaggtc 2924
ggcttcattg acaccgatcc aaacctggag atcattgcac ctgctcgtga ctccgcatgg 2984
acccgcgaca aggtatcgc ctccgagag gagaacaacg ttccaatcga gcagtcctg 3044
aagtcacat tctccatcga ccagaacgtc tggggccgag ctattgagac cggttacctg 3104
gaagatctgt ggaatgctc aaccaaggac atctacgat acaccgagga tccagctctg 3164
ggtaacgctc cagatgaggt catcatctcc ttccagggtg gcaagccagt ctccatcgat 3224
ggcgcgccag tctccgtact gcaggctatt gaagagctga accgtcgtgc aggcgcacag 3284
ggcgttgccc gccttgacat ggttgaggac cgtctcgtgg gcatcaagtc ccgcgaaatc 3344
tacgaagcac caggcgcaat cgcactgatt aaggctcagc aggccttgga agatgtcacc 3404
atcgagcgcg aactggctcg ctacaagcgt ggcgttgacg caggttgggc tgaggaagta 3464
tacgacggcc tgtggttcgg acctctgaag cgctccctgg acgcgttcac tgattccacc 3524
caggagcacg tcaccggcga taccgcatg gttctgcacg caggttccat caccatcaat 3584
ggtcgtcgtt ccagccactc cctgtacgac ttcaacctgg ctacctacga caccggcgac 3644
accttcgacc agacctggc taagggttt gtccagctgc acggtctgtc ctccaagatc 3704
gctaacaagc gcgatcgca agctggcaac aactaagcca ccttttcaag catccagact 3764
agaacttcaa gtatttagaa agtagaaga caccacatgg aacagcacgg aaccaatgaa 3824
ggtgcgctgt ggggcggccg cttctccggt ggacctccg aggcacatgt cgccttgagt 3884
gtctccactc atttcgactg ggttttgccc ccttatgatg tgttgccctc caaggcacac 3944
gccaagggtt tgcaccaagc agagctactt tctgatgaag atctagccac catgctggct 4004
ggtcttgatc agctgggcaa ggatgtgcc gacggaacct tcggtcgct gccttctgat 4064
gaggatgtgc acggcgcgat ggaacgggt ctgattgacc gcgttggtcc tgaggtgggc 4124
ggcgtctgc gcgctggtc ttcccgcaac gaccaggtg caacctgtt ccgcatgtg 4184
gtccgcgacg cagtgcgca catcgcgctg ggaacaaccg agcttgctga c 4235

<210> 18

50

<211> 171

<212> PRT

<213> Brevibacterium flavum

55

<400> 18

EP 1 154 020 A2

Met Ser Leu Gly Ser Thr Pro Ser Thr Pro Glu Asn Leu Asn Pro Val
1 5 10 15
5 Thr Arg Thr Ala Arg Gln Ala Leu Ile Leu Gln Ile Leu Asp Lys Gln
20 25 30
Lys Val Thr Ser Gln Val Gln Leu Ser Glu Leu Leu Asp Glu Gly
35 40 45
10 Ile Asp Ile Thr Gln Ala Thr Leu Ser Arg Asp Leu Asp Glu Leu Gly
50 55 60
Ala Arg Lys Val Arg Pro Asp Gly Gly Arg Ala Tyr Tyr Ala Val Gly
65 70 75 80
15 Pro Val Asp Ser Ile Ala Arg Glu Asp Leu Arg Gly Pro Ser Glu Lys
85 90 95
Leu Arg Arg Met Leu Asp Glu Leu Leu Val Ser Thr Asp His Ser Gly
100 105 110
20 Asn Ile Ala Met Leu Arg Thr Pro Pro Gly Ala Ala Gln Tyr Leu Ala
115 120 125
Ser Phe Ile Asp Arg Val Gly Leu Lys Glu Val Val Gly Thr Ile Ala
130 135 140
25 Gly Asp Asp Thr Val Phe Val Leu Ala Arg Asp Pro Leu Thr Gly Lys
145 150 155 160
Glu Leu Gly Glu Leu Leu Ser Gly Arg Thr Thr
30 165 170

<210> 19
<211> 25
35 <212> DNA
<213> Artificial Sequence

<220>
40 <223> Description of Artificial Sequence:primer for PCR

<400> 19
45 cccgggtttt cttctgcaac tcggg 25

<210> 20
<211> 25
50 <212> DNA
<213> Artificial Sequence

<220>
55 <223> Description of Artificial Sequence:primer for PCR

5 <400> 20
gtcgacaagc tcggttggtc ccage 25

10 <210> 21
<211> 24
<212> DNA
<213> Artificial Sequence

15 <220>
<223> Description of Artificial Sequence:primer for PCR

20 <400> 21
cccctagttc aaggcttggt aatc 24

25 <210> 22
<211> 25
<212> DNA
<213> Artificial Sequence

30 <220>
<223> Description of Artificial Sequence:primer for PCR

35 <400> 22
gtcttacctc ggctggttgg ccage 25

40

Claims

- 45 1. A coryneform bacterium in which an arginine repressor does not function in a normal manner, and which has L-arginine producing ability.
2. The coryneform bacterium according to Claim 1, wherein the arginine repressor does not function in a normal manner due to disruption of a gene coding for the arginine repressor on a chromosome of the bacterium.
- 50 3. The coryneform bacterium according to Claim 2, wherein the arginine repressor has the amino acid sequence shown in SEQ ID NO: 18 or an amino acid sequence showing homology to the amino acid sequence.
- 55 4. A method for producing L-arginine, which comprises culturing a coryneform bacterium according to any one of Claims 1-3 in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

Fig. 1





Fig. 2






Fig. 3

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 154 020 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
22.01.2003 Bulletin 2003/04

(51) Int Cl.7: **C12N 15/31, C12N 1/21,
C07K 14/34, C12P 13/10**

(43) Date of publication A2:
14.11.2001 Bulletin 2001/46

(21) Application number: 01109457.0

(22) Date of filing: 24.04.2001

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 28.04.2000 JP 2000129167

(71) Applicant: Ajinomoto Co., Ltd.
Tokyo (JP)

(72) Inventors:
• Suga, Mikiko, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)

- Asakura, Yoko, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)
- Mori, Yukiko, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)
- Ito, Hisao, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)
- Kurahashi, Osamu, Ajinomoto Co., Inc.
Kawasaki-ku, Kawasaki-shi, Kanagawa (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) **Arginine repressor deficient strain of coryneform bacterium and method for producing L-arginine**

(57) L-Arginine is produced by culturing a coryneform bacterium in which an arginine repressor involved in L-arginine biosynthesis is deleted by disrupting a gene coding for the repressor, and which has L-arginine

producing ability in a medium to produce and accumulate L-arginine in the medium, and collecting the L-arginine from the medium.

EP 1 154 020 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 10 9457

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 3 878 044 A (KUBOTA KOJI ET AL) 15 April 1975 (1975-04-15)	1	C12N15/31 C12N1/21
Y	* column 1, paragraph 2 - paragraph 4; claims 1,2 *	2-4	C07K14/34 C12P13/10
Y	----- DATABASE EMBL 'Online! 6 January 1999 (1999-01-06) KO S.-Y. ET AL.: "Corynebacterium glutamicum arginine repressor (argR) gene, complete cds." retrieved from EBI Database accession no. AF041436 XP002221143 * the whole document *	2-4	
A	----- EP 0 261 627 A (KYOWA HAKKO KOGYO KK) 30 March 1988 (1988-03-30) * page 4, line 15 - line 29 *	1-4	
A	----- EP 0 443 031 A (KYOWA HAKKO KOGYO KK) 28 August 1991 (1991-08-28) * column 1, paragraph 4 *	1-4	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	----- TIAN G ET AL: "Mutational analysis of the arginine repressor of Escherichia coli." MOLECULAR MICROBIOLOGY. ENGLAND AUG 1994, vol. 13, no. 4, August 1994 (1994-08), pages 599-608, XP008010753 ISSN: 0950-382X * abstract *	1-4	C07K C12N
----- -/--			
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 19 November 2002	Examiner Gurdjian, D
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons & : member of the same patent family, corresponding document			

EPD FORM 1503 03/92 (P04C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 01 10 9457

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	<p>MESSENGUY F ET AL: "Determination of the DNA-binding sequences of ARGR proteins to arginine anabolic and catabolic promoters."</p> <p>MOLECULAR AND CELLULAR BIOLOGY. UNITED STATES MAY 1991, vol. 11, no. 5, May 1991 (1991-05), pages 2852-2863, XP008010775</p> <p>ISSN: 0270-7306</p> <p>* abstract *</p> <p>-----</p>	1-4	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search		Date of completion of the search	Examiner
THE HAGUE		19 November 2002	Gurdjian, D
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p> <p>I : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>A : member of the same patent family, corresponding document</p>			

EP 0 FORM 1503 03.92 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 10 9457

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

19-11-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 3878044	A	15-04-1975	ES	419433 A1	01-04-1976
EP 0261627	A	30-03-1988	JP	1994602 C	22-11-1995
			JP	7028749 B	05-04-1995
			JP	63079597 A	09-04-1988
			DE	3785530 D1	27-05-1993
			DE	3785530 T2	18-11-1993
			EP	0261627 A2	30-03-1988
			KR	9004425 B1	25-06-1990
			US	5017482 A	21-05-1991
EP 0443031	A	28-08-1991	JP	3183474 A	09-08-1991
			AU	634268 B2	18-02-1993
			AU	6184990 A	08-04-1991
			CA	2041653 A1	05-03-1991
			EP	0443031 A1	28-08-1991
			NO	9103546 A1	21-03-1991
			US	5217888 A	08-06-1993

EPO FORM P0452

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)